Wave Neuroscience’s MeRT System Receives the US FDA Clearance for PTSD

Shots: The US FDA has granted clearance to the Magnetic EEG-guided Resonance Therapy (MeRT) System, a personalized, biomarker-guided neuromodulation technology for Post-Traumatic Stress Disorder (PTSD) Clearance was supported by a trial conducted with investigators from Texas A&M Health Institute of Biosciences & Technology, demonstrating that MeRT significantly reduced PTSD symptom severity with clinically meaningful improvements…

ByRidhi RastogiJune 12, 2026

NEWS

Akeso Reports the NMPA Approval of Gumokimab to Treat Plaque Psoriasis

Shots: The Chinese NMPA has approved Akeso’s gumokimab (AK111; SC, 17 doses per year, incl. loading) to treat mod. to sev. plaque psoriasis in adults based on the P-III (AK111-301) trial & 3 supportive studies, showing rapid improvement in 2wks. Data showed short-term efficacy, with a PASI 75 response rate approaching 94.6% & PASI 100 reaching…

ByRidhi RastogiJune 12, 2026

NEWS

Takeda Reports P-III (LATITUDE Atlas) Trial Data on Zasocitinib for Plaque Psoriasis (PsO)

Shots: Takeda has reported topline P-III (LATITUDE Atlas) trial data assessing zasocitinib (TAK-279; 30mg, PO, QD) vs deucravacitinib (6mg, QD) in 606 adults with mod. to sev. PsO Trial showed that zasocitinib was superior to deucravacitinib in the 1EP, with improved PASI 100 response rates at Wk. 16, plus in all key 2EPs, incl. PASI 90…

ByRidhi RastogiJune 12, 2026

NEWS

Merck Animal Health to Acquire TARGAN

Shots: Merck Animal Health has entered into a definitive agreement to acquire TARGAN for an undisclosed purchase price; closing is expected in Q3’26 Upon closing, the acquisition will expand MAH’s poultry portfolio with WingScan, an automated chick sorting platform that uses vision tech & proprietary algorithms to identify & sort chicks by gender in real…

ByRidhi RastogiJune 11, 2026

NEWS

J&J Reports the P-II/III (ENERGY) Trial Data on Imaavy for Warm Autoimmune Hemolytic Anemia (wAIHA)

Shots: The P-II/III (ENERGY) trial assessed 2 different dose schedules of J&J's Imaavy vs PBO in 115 adults living with wAIHA for 24wks. followed by an OLE period, where pts received Imaavy for 144wks. with a follow-up of 6wks. after the last assessment In the 30mg/kg group, Imaavy showed mean increase of 1g/dL in Hgb…

ByRidhi RastogiJune 11, 2026

NEWS

Novartis Reports the Biomarker Data from P-I/II (FORTITUDE) study of del-brax in FSHD

Shots: Novartis has reported data from the biomarker cohort of the P-I/II (FORTITUDE) study assessing delpacibart braxlosiran (2mg/kg, Q6W) vs PBO in 90 pts (16-70yrs.) with facioscapulohumeral muscular dystrophy (FSHD) Trial met its 1 & key 2EPs, showing reductions in KHDC1L (cDUX) & creatine kinase biomarker levels, which indicates potent target engagement & decrease in…

ByRidhi RastogiJune 11, 2026

NEWS

Genentech’s Tecentriq Receives the US FDA Priority Review for Stage III dMMR/MSI-H Colon Cancer

Shots: The US FDA has accepted sBLA & granted priority review to adj. Tecentriq (atezolizumab) & Tecentriq Hybreza (atezolizumab & hyaluronidase-tqjs) in combination with CT in stage III dMMR or MSI-H colon cancer (PDUFA: Oct 9, 2026) sBLA was based on the P-III (ATOMIC) trial assessing Tecentriq to FOLFOX6 CT in 712 pts with stage…

ByRidhi RastogiJune 11, 2026

NEWS

GlycoNex Reports the P-III Trial Data on SPD8 (Biosimilar, Denosumab)

Shots: GlycoNex has reported the P-III trial results assessing SPD8 (SC, Q6M), a biosimilar version of denosumab co-developed with Mitsubishi Gas Chemical, vs Prolia in 266 Japanese subjects with osteoporosis Trial met its 1EP, with SPD8 demonstrating therapeutic equivalence to Prolia. The between-group difference in the 1EP & its 95% confidence interval fell within the pre-specified…

ByRidhi RastogiJune 11, 2026

NEWS

XtalPi Secures Over $400M Partnership to Develop GPCR-Targeted Small Molecule Therapy

Shots: XtalPi has entered into a strategic partnership with a biopharmaceutical company to develop an oral small molecule against G protein-coupled receptor XtalPi will leverage its structure-based drug design platform, combining quantum physics, generative AI, large-scale automated chemical synthesis orchestrated by a multi-agent system to accelerate Design-Make-Test-Analyze (DMTA) cycles As per the deal, XtalPi will receive…

ByRidhi RastogiJune 11, 2026

NEWS

Novartis Inks a ~$1.44B Deal with Orionis to Advance Molecular Glue Therapies for Multiple Targets

Shots: Orionis Biosciences has entered into a multi-year collaboration with Novartis to discover & design molecular glue drugs for challenging therapeutic targets across multiple disease areas As per the deal, the companies will leverage Orionis’s Allo-Glue platform & AI-powered discovery engine to accelerate target & ligase profiling, as well as molecular glue optimization, enabling the…

ByRidhi RastogiJune 10, 2026

Ridhi Rastogi

Wave Neuroscience’s MeRT System Receives the US FDA Clearance for PTSD

Akeso Reports the NMPA Approval of Gumokimab to Treat Plaque Psoriasis

Takeda Reports P-III (LATITUDE Atlas) Trial Data on Zasocitinib for Plaque Psoriasis (PsO)

Merck Animal Health to Acquire TARGAN

J&J Reports the P-II/III (ENERGY) Trial Data on Imaavy for Warm Autoimmune Hemolytic Anemia (wAIHA)

Novartis Reports the Biomarker Data from P-I/II (FORTITUDE) study of del-brax in FSHD

Genentech’s Tecentriq Receives the US FDA Priority Review for Stage III dMMR/MSI-H Colon Cancer

GlycoNex Reports the P-III Trial Data on SPD8 (Biosimilar, Denosumab)

XtalPi Secures Over $400M Partnership to Develop GPCR-Targeted Small Molecule Therapy

Novartis Inks a ~$1.44B Deal with Orionis to Advance Molecular Glue Therapies for Multiple Targets

Contact US

FOLLOW US